Health ❯ Healthcare ❯ Patient Care

Medication Adherence

Side Effects Long-term Treatment Side Effects Management Lifestyle Changes Cholesterol Management Quality of Life Oral Medications Injectable Drugs Treatment Outcomes Treatment Accessibility

10 ARTICLES

last mo.

Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven

New oral drugs and cheaper generics are driving interest while cost, injection aversion, uncertain long‑term effects and high payer bills are prompting cautious prescribing and tighter employer coverage.

7 ARTICLES

2mo ago

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

6 ARTICLES

4mo ago

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

18 ARTICLES

5mo ago

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

4 ARTICLES

6mo ago

Columbia Study Pinpoints How Some Statins May Trigger Muscle Pain

3 ARTICLES

6mo ago

Oxford BMJ Review Finds Rapid Weight Rebound After Stopping Modern Weight-Loss Drugs

8 ARTICLES

7mo ago

FDA Clears Wegovy Weight-Loss Pill, U.S. Launch Set for January

3 ARTICLES

7mo ago

Large Swedish Study Finds ARBs Sustain the Best Long-Term Adherence in Hypertension

3 ARTICLES

8mo ago

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

4 ARTICLES

last yr.

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control

7 ARTICLES

last yr.

Italy Rolls Out Weekly Insulin Therapy Despite Regional Disparities

4 ARTICLES

last yr.

Wegovy and Ozempic: Celebrity Trends and Health Risks

3 ARTICLES

last yr.

Study Identifies Key Factors Influencing Weight Loss on GLP-1 RA Medications

7 ARTICLES

last yr.

Weekly Insulin Shots Match Daily Injections in Diabetes Management

Medication Adherence

Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Columbia Study Pinpoints How Some Statins May Trigger Muscle Pain

Oxford BMJ Review Finds Rapid Weight Rebound After Stopping Modern Weight-Loss Drugs

FDA Clears Wegovy Weight-Loss Pill, U.S. Launch Set for January

Large Swedish Study Finds ARBs Sustain the Best Long-Term Adherence in Hypertension

Cryo-EM Study Reveals How Statins Trigger Muscle Damage

Cofepris Authorizes Bi-Monthly Injectable PrEP in Mexico

Never miss stories about

Medication Adherence

Weekly Parkinson’s Injection Secures Patent After Successful Lab Trials

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control

Italy Rolls Out Weekly Insulin Therapy Despite Regional Disparities

Wegovy and Ozempic: Celebrity Trends and Health Risks

Study Identifies Key Factors Influencing Weight Loss on GLP-1 RA Medications

Weekly Insulin Shots Match Daily Injections in Diabetes Management

Never miss stories about

Medication Adherence